Joyoti Dey

1.0k total citations
16 papers, 392 citations indexed

About

Joyoti Dey is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Joyoti Dey has authored 16 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Joyoti Dey's work include Chronic Lymphocytic Leukemia Research (4 papers), Cancer-related Molecular Pathways (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Joyoti Dey is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Cancer-related Molecular Pathways (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Joyoti Dey collaborates with scholars based in United States, South Africa and Switzerland. Joyoti Dey's co-authors include Paul D. Wes, Kien Trinh, Katherine F. Moore, Paul J. Muchowski, Leo J. Pallanck, Richard A. Klinghoffer, William Kerwin, Sally Ditzler, Nianhang Chen and Carrie Baker Brachmann and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and SHILAP Revista de lepidopterología.

In The Last Decade

Joyoti Dey

14 papers receiving 387 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joyoti Dey United States 8 218 107 59 53 53 16 392
Jana K. Sonner Germany 10 236 1.1× 80 0.7× 40 0.7× 80 1.5× 27 0.5× 19 551
Flora Vitale Italy 12 187 0.9× 117 1.1× 45 0.8× 88 1.7× 49 0.9× 16 401
Fangcheng Zhang China 14 188 0.9× 128 1.2× 72 1.2× 96 1.8× 45 0.8× 34 530
Mario Mauri Italy 12 356 1.6× 69 0.6× 31 0.5× 98 1.8× 85 1.6× 30 587
Maria Patrizia Mongiardi Italy 13 289 1.3× 59 0.6× 26 0.4× 57 1.1× 48 0.9× 20 458
Gabriele Seitz Germany 11 240 1.1× 120 1.1× 49 0.8× 77 1.5× 37 0.7× 17 514
Natalia Akentieva Russia 9 250 1.1× 31 0.3× 91 1.5× 78 1.5× 50 0.9× 29 472
Aslι Küçükosmanoğlu Netherlands 8 348 1.6× 134 1.3× 17 0.3× 36 0.7× 53 1.0× 12 572
Lanchun Ni China 13 228 1.0× 45 0.4× 63 1.1× 130 2.5× 39 0.7× 20 464
Janani Sundaresan United States 7 293 1.3× 42 0.4× 39 0.7× 43 0.8× 27 0.5× 12 445

Countries citing papers authored by Joyoti Dey

Since Specialization
Citations

This map shows the geographic impact of Joyoti Dey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyoti Dey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyoti Dey more than expected).

Fields of papers citing papers by Joyoti Dey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyoti Dey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyoti Dey. The network helps show where Joyoti Dey may publish in the future.

Co-authorship network of co-authors of Joyoti Dey

This figure shows the co-authorship network connecting the top 25 collaborators of Joyoti Dey. A scholar is included among the top collaborators of Joyoti Dey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joyoti Dey. Joyoti Dey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Lü, Min, et al.. (2024). KT-253, a Highly Potent and Selective MDM2 Protein Degrader, Eliminates Malignant Myelofibrosis Stem/Progenitor Cells. Blood. 144(Supplement 1). 3588–3588. 1 indexed citations
2.
Ivanova, Ellie, Cosmin Tegla, Alberto Herrera, et al.. (2022). Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader. Blood. 140(Supplement 1). 3557–3558. 1 indexed citations
3.
Starodub, Alexander, Ashwin Gollerkeri, Chris De Savi, et al.. (2022). Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS3171–TPS3171. 13 indexed citations
4.
Smith, Stephen D., Alexander Starodub, Don A. Stevens, et al.. (2022). A Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors. Blood. 140(Supplement 1). 12024–12025. 7 indexed citations
5.
Dey, Joyoti, Phillip Liu, Michele Mayo, et al.. (2021). 603 Targeted STAT3 degradation leads to remodeling of an immunosuppressive tumor microenvironment and subsequent sensitization to immune checkpoint therapy. SHILAP Revista de lepidopterología. A633–A633.
6.
Dixit, Vaishali, Michele Mayo, Joyoti Dey, et al.. (2021). A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers. Blood. 138(Supplement 1). 1865–1865. 14 indexed citations
7.
Rong, Haojing, Kirti Sharma, Bin Yang, et al.. (2020). Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma. Blood. 136(Supplement 1). 42–42.
8.
Hatton, Beryl A., Marc Grenley, James Garnsey, et al.. (2019). Abstract 4136: Direct intratumoral microdosing via the CIVO® platform reveals anti-tumor immune responses induced by the SUMO inhibitor TAK-981. Cancer Research. 79(13_Supplement). 4136–4136. 1 indexed citations
9.
Dey, Joyoti, Thomas L. Deckwerth, William Kerwin, et al.. (2017). Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Scientific Reports. 7(1). 72 indexed citations
10.
Dey, Joyoti, William Kerwin, Marc Grenley, et al.. (2016). A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo. PLoS ONE. 11(6). e0158617–e0158617. 6 indexed citations
11.
Dey, Joyoti, Sally Ditzler, Matthew C. Biery, et al.. (2016). Abstract 2835: Voruciclib, a clinical stage oral CDK inhibitor, sensitizes triple negative breast cancer xenografts to proteasome inhibition. Cancer Research. 76(14_Supplement). 2835–2835. 2 indexed citations
12.
Chen, Nianhang, Carrie Baker Brachmann, Xiping Liu, et al.. (2015). Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemotherapy and Pharmacology. 76(4). 699–712. 89 indexed citations
13.
Dey, Joyoti, Adrian M. Dubuc, Kyle D. Pedro, et al.. (2013). MyoD Is a Tumor Suppressor Gene in Medulloblastoma. Cancer Research. 73(22). 6828–6837. 23 indexed citations
14.
Diede, Scott J., Zizhen Yao, Ashlee E. Tyler, et al.. (2013). Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. Epigenetics. 8(12). 1254–1260. 15 indexed citations
15.
Dey, Joyoti, Sally Ditzler, Sue E. Knoblaugh, et al.. (2012). A Distinct Smoothened Mutation Causes Severe Cerebellar Developmental Defects and Medulloblastoma in a Novel Transgenic Mouse Model. Molecular and Cellular Biology. 32(20). 4104–4115. 35 indexed citations
16.
Trinh, Kien, Katherine F. Moore, Paul D. Wes, et al.. (2008). Induction of the Phase II Detoxification Pathway Suppresses Neuron Loss inDrosophilaModels of Parkinson's Disease. Journal of Neuroscience. 28(2). 465–472. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jana K. Sonner Breakdown of academic impact, for papers by Flora Vitale Breakdown of academic impact, for papers by Fangcheng Zhang Breakdown of academic impact, for papers by Mario Mauri Breakdown of academic impact, for papers by Maria Patrizia Mongiardi Breakdown of academic impact, for papers by Gabriele Seitz Breakdown of academic impact, for papers by Natalia Akentieva Breakdown of academic impact, for papers by Aslι Küçükosmanoğlu Breakdown of academic impact, for papers by Lanchun Ni Breakdown of academic impact, for papers by Janani Sundaresan
Rankless by CCL
2026